Bank of Montreal Can boosted its position in Celgene Corporation (NASDAQ:CELG) by 2.5% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 3,382,220 shares of the biopharmaceutical company’s stock after purchasing an additional 82,232 shares during the period. Bank of Montreal Can owned about 0.43% of Celgene Corporation worth $439,249,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of the stock. Harel Insurance Investments & Financial Services Ltd. purchased a new stake in shares of Celgene Corporation during the first quarter worth $118,000. Oakworth Capital Inc. lifted its position in shares of Celgene Corporation by 60.9% during the first quarter. Oakworth Capital Inc. now owns 1,089 shares of the biopharmaceutical company’s stock worth $136,000 after acquiring an additional 412 shares in the last quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. lifted its position in shares of Celgene Corporation by 47.5% during the first quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 1,180 shares of the biopharmaceutical company’s stock worth $147,000 after acquiring an additional 380 shares in the last quarter. Independent Portfolio Consultants Inc. lifted its position in shares of Celgene Corporation by 209.4% during the first quarter. Independent Portfolio Consultants Inc. now owns 1,541 shares of the biopharmaceutical company’s stock worth $192,000 after acquiring an additional 1,043 shares in the last quarter. Finally, Schmidt P J Investment Management Inc. purchased a new stake in shares of Celgene Corporation during the first quarter worth $201,000. Institutional investors and hedge funds own 79.33% of the company’s stock.

A number of equities research analysts recently issued reports on CELG shares. Leerink Swann upgraded Celgene Corporation from a “market perform” rating to an “outperform” rating and increased their price objective for the stock from $94.42 to $150.00 in a research report on Friday, June 16th. They noted that the move was a valuation call. William Blair reiterated an “outperform” rating on shares of Celgene Corporation in a research report on Monday, June 26th. Cantor Fitzgerald reiterated a “buy” rating on shares of Celgene Corporation in a research report on Monday, August 28th. BTIG Research downgraded Celgene Corporation from a “buy” rating to a “neutral” rating and increased their price objective for the stock from $96.93 to $131.70 in a research report on Friday, June 30th. Finally, BidaskClub upgraded Celgene Corporation from a “sell” rating to a “hold” rating in a research report on Wednesday, June 21st. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating, twenty-one have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average price target of $149.34.

Shares of Celgene Corporation (CELG) traded down 0.45% during midday trading on Friday, hitting $143.13. 1,321,999 shares of the company traded hands. Celgene Corporation has a 52 week low of $96.93 and a 52 week high of $144.00. The company has a 50-day moving average price of $135.45 and a 200-day moving average price of $127.81. The stock has a market capitalization of $111.98 billion, a P/E ratio of 44.33 and a beta of 1.89.

Celgene Corporation (NASDAQ:CELG) last posted its earnings results on Thursday, July 27th. The biopharmaceutical company reported $1.82 EPS for the quarter, beating the Zacks’ consensus estimate of $1.61 by $0.21. Celgene Corporation had a net margin of 21.35% and a return on equity of 68.51%. The company had revenue of $3.27 billion during the quarter, compared to analysts’ expectations of $3.23 billion. During the same quarter in the prior year, the company posted $1.44 earnings per share. Celgene Corporation’s revenue for the quarter was up 18.7% compared to the same quarter last year. Analysts anticipate that Celgene Corporation will post $7.32 earnings per share for the current fiscal year.

In related news, Director Gilla Kaplan sold 9,250 shares of the stock in a transaction that occurred on Tuesday, September 12th. The shares were sold at an average price of $141.56, for a total transaction of $1,309,430.00. Following the completion of the sale, the director now owns 85,551 shares of the company’s stock, valued at $12,110,599.56. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director James J. Loughlin sold 18,500 shares of the stock in a transaction that occurred on Monday, June 26th. The shares were sold at an average price of $133.57, for a total transaction of $2,471,045.00. Following the sale, the director now directly owns 32,877 shares of the company’s stock, valued at approximately $4,391,380.89. The disclosure for this sale can be found here. Insiders have sold 63,006 shares of company stock valued at $8,490,806 in the last three months. 0.95% of the stock is currently owned by corporate insiders.

TRADEMARK VIOLATION NOTICE: This piece of content was first posted by Daily Political and is the sole property of of Daily Political. If you are viewing this piece of content on another publication, it was stolen and reposted in violation of United States & international copyright and trademark laws. The correct version of this piece of content can be read at https://www.dailypolitical.com/2017/09/22/celgene-corporation-celg-shares-bought-by-bank-of-montreal-can.html.

Celgene Corporation Profile

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Institutional Ownership by Quarter for Celgene Corporation (NASDAQ:CELG)

Receive News & Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related companies with MarketBeat.com's FREE daily email newsletter.